Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Consolidated Edison, Inc. (ED) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance

Consolidated Edison, Inc.Trade
Royalty Pharma plc Class A Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

Consolidated Edison, Inc. vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $39.20B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Consolidated Edison, Inc. is the larger of the two by market cap, and Consolidated Edison, Inc. pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.

EDRPRX
Market Cap
$39.20B$25.27B
Volume
2,142,9003,671,183
Sector
UtilitiesHealth
52-Week High
$115.46$63.96
52-Week Low
$95.37$35.44
Typical Hold Time
75 Days0 Days
Enterprise Value
$66.05B$32.50B
Dividend Yield
3.31%1.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Consolidated Edison, Inc.

Consolidated Edison (ED) trades at $104.65, down 0.45% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported revenue of $16.92B and net income of $2.02B for 2025, with a net margin of 11.95%. Recent earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026. The stock is supported by a strong dividend history, with a recent $0.89 dividend declared for H2 2026, and positive news highlighting its economic impact in New York and involvement in electric bus infrastructure.

The outlook for ED is cautiously optimistic, with a consensus price target of $106.33 suggesting modest upside. Strengths include stable cash flow, a solid dividend, and strategic investments in infrastructure. Key risks involve fluctuating earnings, high debt levels, and regulatory pressures. Analyst sentiment is predominantly neutral, with 62.96% hold ratings, indicating a wait-and-see approach amid evolving utility sector dynamics.

Royalty Pharma plc Class A Ordinary Shares

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ED

No sentiment data available yet.

RPRX
100% Buy0% Sell
Avg holding period · 0 Days

About Consolidated Edison, Inc.

Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.

Read more on ED →

About Royalty Pharma plc Class A Ordinary Shares

Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.

Read more on RPRX →